Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients. 2023

Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
Department of Infectious Diseases, Alfred Health and Central Clinical School, Monash University, Melbourne, Victoria, Australia.

The frequency and significance of cytomegalovirus (CMV) infection in seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative recommendations mostly extrapolated from other groups. We evaluated the incidence and severity of CMV infection in R+ HTR, to identify risk factors and describe outcomes. R+ HTR from 2010 to 2019 were included. Antiviral prophylaxis was not routinely used, with clinically guided monitoring the local standard of care. The primary outcome was CMV infection within one-year post-transplant; secondary outcomes included other herpesvirus infections and mortality. CMV infection occurred in 27/155 (17%) R+ HTR. Patients with CMV had a longer hospitalization (27 vs. 20 days, unadjusted HR 1.02, 95% CI 1.00-1.02, p = .01), higher rate of intensive care readmission (26% vs. 9%, unadjusted HR 3.46, 1.46-8.20, p = .005), and increased mortality (33% vs. 8%, unadjusted HR 10.60, 4.52-24.88, p < .001). The association between CMV and death persisted after adjusting for multiple confounders (HR 24.19, 95% CI 7.47-78.30, p < .001). Valganciclovir prophylaxis was used in 35/155 (23%) and was protective against CMV (infection rate 4% vs. 27%, adjusted HR .07, .01-.72, p = .025), even though those receiving it were more likely to have received thymoglobulin (adjusted OR 10.5, 95% CI 2.01-55.0, p = .005). CMV infection is common in R+ HTR and is associated with a high burden of disease and increased mortality. Patients who received valganciclovir prophylaxis were less likely to develop CMV infection, despite being at higher risk. These findings support the routine use of antiviral prophylaxis following heart transplantation in all CMV R+ patients.

UI MeSH Term Description Entries
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077562 Valganciclovir A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor. Ganciclovir L-valyl Ester,Valcyt,Valcyte,Valganciclovir Hydrochloride,Ganciclovir L valyl Ester
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015774 Ganciclovir An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. BIOLF-62,BW-759,Cytovene,Ganciclovir Sodium,Ganciclovir, Monosodium Salt,Gancyclovir,RS-21592
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016027 Heart Transplantation The transference of a heart from one human or animal to another. Cardiac Transplantation,Grafting, Heart,Transplantation, Cardiac,Transplantation, Heart,Cardiac Transplantations,Graftings, Heart,Heart Grafting,Heart Graftings,Heart Transplantations,Transplantations, Cardiac,Transplantations, Heart
D066027 Transplant Recipients Individuals receiving tissues or organs transferred from another individual of the same or different species, or from within the same individual. Recipient, Transplant,Recipients, Transplant,Transplant Recipient

Related Publications

Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
December 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
June 2014, Transplant infectious disease : an official journal of the Transplantation Society,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
June 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
July 1992, Journal of clinical pathology,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
September 1989, Archives of internal medicine,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
August 1990, Transplantation proceedings,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
October 2018, Expert review of clinical pharmacology,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
May 2017, Pediatric transplantation,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
January 2009, Transplantation proceedings,
Bradley J Gardiner, and Jessica P Bailey, and Mia A Percival, and Beth A Morgan, and Victoria M Warner, and Sue J Lee, and C Orla Morrissey, and David M Kaye, and Anton Y Peleg, and Andrew J Taylor
July 2015, Clinics (Sao Paulo, Brazil),
Copied contents to your clipboard!